CELLDEX THERAPEUTICS, INC.

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
C07K PEPTIDES 3799
 
  
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 36219
 
  
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 8198
 
  
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 6161
 
  
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 396
 
  
 
C12Q MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS 3122
 
  
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 293
 
  
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 247
 
  
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 297
 
  
 
B01D SEPARATION 1133

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2018/0066,053 AGONISTIC ANTIBODIES THAT BIND HUMAN CD40 AND USES THEREOFApr 18, 17Mar 08, 18[C07K]
2018/0057,595 Anti-MET Antibodies and Methods of Use ThereofMar 15, 16Mar 01, 18[A61K, C07K]
2018/0043,014 Compositions Using Antibodies Directed to GPNMB and Uses ThereofJun 20, 17Feb 15, 18[A61K, C07K]
2017/0368,172 USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENTJun 03, 17Dec 28, 17[A61K, C07K]
2017/0240,648 ANTI-ERBB ANTIBODIES AND METHODS OF USE THEREOFApr 10, 15Aug 24, 17[G01N, C07K]
2017/0218,067 Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen and Uses ThereofFeb 24, 17Aug 03, 17[A61K, G01N, C07K]
2017/0190,788 USES OF ANTI-HER3 ANTIBODIES FOR TREATING CANCERSep 10, 15Jul 06, 17[A61K, C07K]
2017/0129,947 REGULATING THE INTERACTION BETWEEN TAM LIGANDS AND LIPID MEMBRANES WITH EXPOSED PHOSPHATIDYL SERINESep 20, 16May 11, 17[A61K, C07K]
2017/0100,428 REGULATORS OF ANAPLASTIC LYMPHOMA KINASE AND USES THEREOFMay 29, 15Apr 13, 17[A61K, C12Q, G01N, C07K]
2016/0311,919 Antibodies Directed To GPNMB And Uses ThereofFeb 25, 16Oct 27, 16[A61K, C07K]

View all Publication..

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9649356 Method of improving transplant function using soluble complement receptor type I (sCR1)Oct 27, 11May 16, 17[A61K, A01N, C07K]
9649357 Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)Mar 16, 16May 16, 17[A61K]
9624300 Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)Dec 17, 12Apr 18, 17[A61K, C12P, C07K]
9605081 Polynucleotides encoding anti-kit antibodiesMar 30, 16Mar 28, 17[A61K, C12N, G01N, C07K]
9580503 Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereofNov 29, 11Feb 28, 17[A61K, C07K]
9334332 Anti-kit antibodiesJul 24, 13May 10, 16[A61K, C07K]
9295713 Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)Sep 15, 11Mar 29, 16[A61K, A61P]
9259459 Antibody vaccine conjugates and uses thereforJul 30, 04Feb 16, 16[A61K, C07K]
9243064 Antibody vaccine conjugates and uses thereforJan 30, 04Jan 26, 16[A61K, C07K]
9169325 Antibodies that bind human CD27 and uses thereofApr 13, 11Oct 27, 15[A61K, C07K]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2015/0232,948 Method of Detecting and Treating Tuberous Sclerosis Complex Associated DisordersAbandonedMay 07, 15Aug 20, 15[C12Q, C12N, C07K]
2015/0164,800 REGULATING THE INTERACTION BETWEEN TAM LIGANDS AND LIPID MEMBRANES WITH EXPOSED PHOSPHATIDYL SERINEAbandonedJul 23, 13Jun 18, 15[A61K, C12Q]
2015/0044,212 Antibodies Directed to GPNMB and Uses ThereofAbandonedAug 07, 14Feb 12, 15[A61K, C07K]
2014/0314,780 Compositions Using Antibodies Directed to GPNMB and Uses ThereofAbandonedJul 01, 14Oct 23, 14[A61K]
2013/0244,255 ANTIBODIES DIRECTED TO GPNMB AND USES THEREOFAbandonedFeb 07, 12Sep 19, 13[G01N]
2013/0202,527 Method of Treating Ovarian and Renal Cancer Using Antibodies Against T Cell Immunoglobulin Domain And Mucin Domain 1 (TIM-1) AntigenAbandonedApr 15, 13Aug 08, 13[C07K]
8318165 Antibodies against human melanoma-associated chondroitin sulphate proteoglycan (MCSP)ExpiredSep 10, 07Nov 27, 12[A61K]
2012/0213,771 ANTIBODIES THAT BIND HUMAN CD27 AND USES THEREOFAbandonedOct 19, 11Aug 23, 12[A61K, C12N, G01N, A61P, C07K]
2011/0053,863 METHODS OF USING FLT3-LIGAND IN THE TREATMENT OF CANCERAbandonedMay 06, 09Mar 03, 11[A61K, A61P]
2009/0142,362 Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)AbandonedNov 06, 07Jun 04, 09[A61K]
2009/0075,886 Dendritic cell stimulatory factorAbandonedAug 07, 08Mar 19, 09[A61K, A61P]
7405270 CD40-Ligand lacking native-pattern glycosylationExpiredJul 19, 02Jul 29, 08[C07K]
7361330 Methods of using flt3-ligand in the treatment of fibrosarcomaExpiredSep 11, 02Apr 22, 08[A61K]
7294331 Methods of using flt3-ligand in hematopoietic cell transplantationExpiredDec 05, 02Nov 13, 07[A61K]
2007/0207,164 Methods of using flt3-ligand in the treatment of cancerAbandonedJun 08, 06Sep 06, 07[A61K]
2007/0004,625 Use of complement inhibitory proteins to treat spinal cord injuryAbandonedJun 30, 05Jan 04, 07[A61K]
7150992 Methods of preparing dendritic cells with flt3-ligand and antigenExpiredOct 30, 00Dec 19, 06[C12N]
2006/0204,508 Treatment of autoimmune diseases using an activator for the notch signalling pathwayAbandonedJul 25, 05Sep 14, 06[A61K]
7078036 Modulation of cholesteryl ester transfer protein (CETP) activityExpiredAug 30, 01Jul 18, 06[A61K]
7074407 Method for increasing HDL cholesterol levelExpiredMar 10, 00Jul 11, 06[A61K]

View all patents..

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.